Abstract:Herpes simplex virus 1 (HSV-1) switches between two infection programs, productive ("lytic") and latent infection. Some HSV-1 microRNAs (miRNAs) have been hypothesized to help control this switch, and yet little is known about regulation of their expression. Using Northern blot analyses, we found that, despite inherent differences in biogenesis efficiency among six HSV-1 miRNAs, all six exhibited high pre-miRNA/miRNA ratios during lytic infection of different cell lines and, when detectable, in acutely infected mouse trigeminal ganglia. In contrast, considerably lower ratios were observed in latently infected ganglia and in cells transduced with lentiviral vectors expressing the miRNAs, suggesting that HSV-1 lytic infection blocks miRNA biogenesis. This phenomenon is not specific to viral miRNAs, as a host miRNA expressed from recombinant HSV-1 also exhibited high pre-miRNA/miRNA ratios late during lytic infection. The levels of most of the mature miRNAs remained stable during infection in the presence of actinomycin D, indicating that the high ratios are due to inefficient pre-miRNA conversion to miRNA. Cellular fractionation experiments showed that late (but not early) during infection, pre-miRNAs were enriched in the nucleus and depleted in the cytoplasm, indicating that nuclear export was blocked. A mutation eliminating ICP27 expression or addition of acyclovir reduced pre-miRNA/miRNA ratios, but mutations drastically reducing Us11 expression did not. Thus, HSV-1 lytic infection inhibits miRNA biogenesis at the step of nuclear export and does so in an ICP27-and viral DNA synthesis-dependent manner. This mechanism may benefit the virus by reducing expression of repressive miRNAs during lytic infection while permitting elevated expression during latency. IMPORTANCE Various mechanisms have been identified by which viruses target host small RNA biogenesis pathways to achieve optimal infection outcomes. Herpes simplex virus 1 (HSV-1) is a ubiquitous human pathogen whose successful persistence in the host entails both productive ("lytic") and latent infection. Although many HSV-1 miRNAs have been discovered and some are thought to help control the lytic/latent switch, little is known about regulation of their biogenesis. By characterizing expression of both pre-miRNAs and mature miRNAs under various conditions, this study revealed striking differences in miRNA biogenesis between lytic and latent infection and uncovered a regulatory mechanism that blocks pre-miRNA nuclear export and is dependent on viral protein ICP27 and viral DNA synthesis. This mechanism represents a new virus-host interaction that could limit the repressive effects of HSV-1 miRNAs hypothesized to promote latency and may shed light on the regulation of miRNA nuclear export, which has been relatively unexplored.

Two Cellular Micrornas, Mir-196B and Mir-1290, Contribute to HIV-1 Latency

Identify Potential Regulators in Hiv-1 Latency by Joint Microrna and Mrna Analysis

High-throughput Sequencing Identifies HIV-1-replication- and Latency-Related Mirnas in CD4+ T Cell Lines.

Regulation of Host and Virus Genes by Neuronal Mir-138 Favours Herpes Simplex Virus 1 Latency.

Herpes Simplex Virus 1 Lytic Infection Blocks MicroRNA (miRNA) Biogenesis at the Stage of Nuclear Export of Pre-miRNAs.

Identification of CD98 As a Novel Biomarker for HIV-1 Permissiveness and Latent Infection

Microrna-155 is A Biomarker of T-Cell Activation and Immune Dysfunction in Hiv-1-Infected Patients

CBX4 Contributes to HIV-1 Latency by Forming Phase-Separated Nuclear Bodies and SUMOylating EZH2.

Hsa-Mir-181-5p Inhibits Human Immunodeficiency Virus Type 1 Replication by Downregulating DDX3X Expression.

Cellular Micrornas Up-Regulate Transcription Via Interaction with Promoter TATA-box Motifs

MicroRNA-181 Expression Regulates Specific Post-Transcriptional Level of SAMHD1 Expression in Vitro.

Biological function of microRNA in HIV-1 infection:summary of recent progress

Profiles of MicroRNAs in Interleukin-27-Induced HIV-Resistant T Cells: Identification of a Novel Antiviral MicroRNA

miRNAs and human immunodeficiency virus type 1 infection:biomarkers and antiviral therapy

miRNA-1236 inhibits HIV-1 infection of monocytes by repressing translation of cellular factor VprBP.

hsa-miR-181-5p inhibits human immunodeficiency virus type 1 replication by downregulating DDX3X expression

New Potential MicroRNA Biomarkers in Human Immunodeficiency Virus Elite Controllers, Human Immunodeficiency Virus Infections, and Coinfections with Hepatitis B Virus or Hepatitis C Virus

MicroRNA Binding to the HIV-1 Gag Protein Inhibits Gag Assembly and Virus Production.

MicroRNAs and long non-coding RNAs during transcriptional regulation and latency of HIV and HTLV

[HIV-1 Infection Changes Mirna Expression Profile in the Whole Blood].

hsa-miR-191-5p inhibits replication of human immunodeficiency virus type 1 by downregulating the expression of NUP50